US Patent

US10980788 — Therapy for treating malignancies

Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2039-06-07 · 13y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for treating cancers in patients with an IDH1 mutation using an IDH1 enzyme inhibitor.

USPTO Abstract

Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme.

Drugs covered by this patent

Tibsovo (IVOSIDENIB) · Servier

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3214`	—	Tibsovo

Patent Metadata

Patent number: US10980788
Jurisdiction: US
Classification: Method of Use
Expires: 2039-06-07
Drug substance claim: No
Drug product claim: No
Assignee: Agios Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.